logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ 50 Mg/day

Pfizer Inc. (PFE) announced new data on PRISTIQ (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder, or MDD, in adults, including a long-term relapse prevention study.

According to the company, these new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety profile of PRISTIQ for the treatment of MDD. Lastly, new data also provide information regarding the discontinuation of PRISTIQ 50 mg/day for the treatment of adults with MDD.

These new PRISTIQ 50 mg/day data focus on key factors - efficacy, safety, long-term use and discontinuation - that clinicians often consider when assessing antidepressants for the treatment of MDD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Allegiant Air will start offering service from Newark Liberty International Airport, after the low-cost airlines received approval from the Federal Aviation Administration. Allegiant will begin offering flights in November between Newark and Cincinnati, Ohio; Savannah, Georgia; Asheville, North Carolina... Theme park chain Six Flags Entertainment Corp. (SIX) announced that it is in "discussions" with the Kingdom of Saudi Arabia to open multiple amusement parks in the conservative Muslim kingdom. Texas-based Six Flags Entertainment says it "has initiated discussions with the government of Saudi Arabia... Uber has developed new software that will track and inform drivers of the ride-hailing app about things like sudden acceleration, harsh braking or whether they are holding their phones while driving. The software is part of an updated version of Uber's app for drivers.
comments powered by Disqus
Follow RTT